salmeterol xinafoate has been researched along with Idiopathic Parkinson Disease in 1 studies
salmeterol : A racemate consisting of equal parts of (R)- and (S)-salmeterol. It is a potent and selective beta2-adrenoceptor agonist (EC50 = 5.3 nM). Unlike other beta2 agonists, it binds to the exo-site domain of beta2 receptors, producing a slow onset of action and prolonged activation.
2-(hydroxymethyl)-4-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)phenol : A phenol having a hydroxymethyl group at C-2 and a 1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl group at C-4; derivative of phenylethanolamine.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Weichert, D | 1 |
| Stanek, M | 1 |
| Hübner, H | 1 |
| Gmeiner, P | 1 |
1 other study available for salmeterol xinafoate and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Structure-guided development of dual β2 adrenergic/dopamine D2 receptor agonists.
Topics: Adrenergic beta-2 Receptor Agonists; Animals; Benzoxazines; CHO Cells; Cricetulus; Dopamine Agonists | 2016 |